Search
Lactitol
go.drugbank.com/drugs/DB12942Approved[A190918] It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). … [A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803]
Categories: Compounds used in a research, industrial, or household settingIodine povacrylex
go.drugbank.com/drugs/DB09537ApprovedIt is a broad spectrum antiseptic and can provide almost 99.9% antiseptic conditions. It is intended for local use only.
Mixtures: 3M DuraPrep SurgicalTixocortol
go.drugbank.com/drugs/DB09091ApprovedWithdrawnIt is a synthetic steroid with topical anti-inflammatory properties without the systemic glucocorticoid and mineralocorticoid activities and toxicity.[L1078]
Tezepelumab
go.drugbank.com/drugs/DB15090ApprovedInvestigationalIt was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca. … [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712]
Synonyms: AMG 157, AMG-157Products: Tezspire 210 mg/1,91 ml Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem (1 adet)Trioxsalen
go.drugbank.com/drugs/DB04571ApprovedWithdrawnIt is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo and hand eczema. … The photoactivated form produces interstrand linkages in DNA resulting in cell apoptosis.
Products: Trisoralen Tab 5mgSamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigational[A235623, A235638, L34359] Although antipsychotic-induced weight gain is incompletely understood, it is thought that the opioid system plays a key role in feeding and metabolism, such that opioid antagonism … an attractive candidate for oral dosing.
Pirtobrutinib
go.drugbank.com/drugs/DB17472ApprovedInvestigational[A256788] In January 2023, the use of pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy was approved under the FDA's Accelerated … Although the mechanisms of resistance to covalent BTK inhibitors have not been fully elucidated, it appears that the presence of Cys481 mutations is the most common reason for resistance to covalent BTK
Ceftibuten
go.drugbank.com/drugs/DB01415ApprovedInvestigationalIt is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.
Mixtures: BUCEF PLUS 180/62.5 MG TOZ ICEREN SASE, 20 ADET, BUCEF PLUS 90/62.5 MG TOZ ICEREN SASE, 20 ADETSynonyms: (+)-(6R,7R)-7-((Z)-2-(2-amino-4-thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acidMucor racemosus
go.drugbank.com/drugs/DB10808ApprovedMucor racemosus extract is used in allergenic testing.
Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureEvinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigational[A229278] In February 2021, evinacumab became the first-and-only inhibitor of ANGPTL3 to receive FDA approval after it was granted approval for the adjunctive treatment of homozygous familial hypercholesterolemia … cardiovascular risk, and it was these observations that provided a rationale for the development of a therapy targeted against ANGPTL3.